Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAFV600E inhibition and can be targeted to reduce resistance

Oncogene

Volumn 34, Issue 7, 2015, Pages 857-867

  Serasinghe, M N ^a,b,c   Missert, D J ^a,b,c,d   Asciolla, J J ^a,b,c   Podgrabinska, S ^a,c   Wieder, S Y ^a,b,c   Izadmehr, S ^b,d   Belbin, G ^a,d   Skobe, M ^a,c,d   Chipuk, J E ^a,b,c,d,e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Department of Dermatology ^*  (United States)

^c Tisch Cancer Institute   (United States)

^d Mount Sinai Graduate School of Biological Sciences   (United States)

^e Diabetes   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; B RAF KINASE; BH3 PROTEIN; BIM PROTEIN; CYTOCHROME C; MITOGEN ACTIVATED PROTEIN KINASE 1; NAVITOCLAX; PROTEIN BCL 2; VEMURAFENIB; ABT-737; BCL2 PROTEIN, HUMAN; BIPHENYL DERIVATIVE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; NITROPHENOL; PIPERAZINE DERIVATIVE; SULFONAMIDE;

A375 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL FATE; CELL FRACTIONATION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TUMOR VOLUME; AMINO ACID SUBSTITUTION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; MISSENSE MUTATION; PATHOLOGY; TUMOR CELL LINE;

AMINO ACID SUBSTITUTION; APOPTOSIS; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; MELANOMA; MUTATION, MISSENSE; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 84938545151     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.21     Document Type: Article

References (30)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
2. Whittaker S, Kirk R, Hayward R, Zambon A, Viros A, Cantarino N et al. Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Transl Med 2010;2:35ra41.
3. Young A, Lyons J, Miller AL, Phan VT, Alarcon IR, McCormick F. Ras signaling and therapies. Adv Cancer Res 2009;102:1-17.
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
5. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007;445:851-857.
6. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA et al. Inhibition of mutated, activated BRAF in metastatic melanoma. New Engl J Med 2010;363:809-819.
7. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009;283:125-134.
8. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 2010;107:14903-14908.
9. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E). Nature 2011;480:387-390.
10. Poulikakos PI, Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 2011;19:11-15.
11. Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008;8:121-132.
12. Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol 2008;18:157-164.
13. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010;37:299-310.
14. Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, Schneiter R et al. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 2002;111:331-342.
15. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002;2:183-192.
16. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005;17:525-535.
17. Chipuk JE, Fisher JC, Dillon CP, Kriwacki RW, Kuwana T, Green DR. Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Proc Natl Acad Sci USA 2008;105:20327-20332.
18. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19:202-208.
19. Anvekar RA, Asciolla JJ, Missert DJ, Chipuk JE. Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatment. Front Oncol 2011;1:34.
20. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-3428.
21. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-681.
22. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. New Engl J Med 2012;366:707-714.
23. McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB et al. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 2012;30:1628-1634.
24. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S et al. Programmed anuclear cell death delimits platelet life span. Cell 2007;128:1173-1186.
25. Hsu YT, Youle RJ. Nonionic detergents induce dimerization among members of the Bcl-2 family. J Biol Chem 1997;272:13829-13834.
26. Asciolla JJ, Renault TT, Chipuk JE. Examining BCL-2 Family Function with large unilamellar vesicles. J Vis Exp 2012;68:1-6.
27. Anvekar RA, Asciolla JJ, Lopez-Rivera E, Floros KV, Izadmehr S, Elkholi R et al. Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens. Cell Death Dis 2012;3:e420.
28. Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, Scott CL. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 2008;118:3651-3659.
29. Suzuki M, Youle RJ, Tjandra N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 2000;103:645-654.
30. Logue SE, Elgendy M, Martin SJ. Expression, purification and use of recombinant annexin V for the detection of apoptotic cells. Nat Protoc 2009;4:1383-1395.